Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;38(1):184-186.
doi: 10.1007/s12288-021-01456-3. Epub 2021 Jun 16.

Adenoviral Subacute Focal Meningoencephalitis Complicating Polatuzumab, Bendamustine and Rituximab Chemo-Immunotherapy for Aggressive B-Cell Lymphoma

Gurvin Chander  1 , Emmanouil Nikolousis  1 , Husam Osman  2 , Ellen Shirley  1 , Bhuvan Kishore  1 , Richard Lovell  1 , Jayna Mistry  1 , Shankara Paneesha  1 , Alexandros Kanellopoulos  3   4
Affiliations

Adenoviral Subacute Focal Meningoencephalitis Complicating Polatuzumab, Bendamustine and Rituximab Chemo-Immunotherapy for Aggressive B-Cell Lymphoma

Gurvin Chander et al. Indian J Hematol Blood Transfus. 2022 Jan.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
a Coronal FLAIR (left) and b axial (right) depicting two MRI Head images of the patient. Note the high T2 signal change worse in the temporal lobes, more prominent in the right lobe. Lymphocyte count was 0.42 × 109/L at the time of this presentation
See this image and copyright information in PMC

References

    1. Vidal LR, de Almeida SM, Cavalli BM, Dieckmann TG, Raboni SM, Salvador GLO, Pereira LA, Rotta I, Nogueira MB. Human adenovirus meningoencephalitis: a 3-years’ overview. J Neurovirol. 2019;25(4):589–596. doi: 10.1007/s13365-019-00758-7. - DOI - PubMed
    1. Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, Assouline S, Kim TM, Kim WS, Ozcan M, Hirata J, Penuel E, Paulson JN, Cheng J, Ku G, Matasar MJ. PolatuzumabVedotin in relapsed or refractory diffuse large B-cell lymphoma. J ClinOncol. 2020;38(2):155–165. doi: 10.1200/JCO.19.00172. - DOI - PMC - PubMed
    1. National Institute for Health and Care Excellence (2020) Polatuzumabvedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma. [cited 2021 February 1]. https://www.nice.org.uk/guidance/ta649/resources/polatuzumab-vedotin-wit...
    1. Martínez-Calle N, Hartley S, Ahearne M, Kasenda B, Beech A, Knight H, Balotis C, Kennedy B, Wagner S, Dyer MJS, Smith D, McMillan AK, Miall F, Bishton M, Fox CP. Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis. Br J Haematol. 2019;184(6):957–968. - PubMed

LinkOut - more resources